Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 18/20 | 0.56 |
| ▸ | TNF | P01375 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401634 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2418982 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL29575414 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL9084958 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2453889 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2417963 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL14762587 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2451299 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL3986349 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL30869073 | 1.00 | TLR2 (0.56) | TLR2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090658-A1 | POLYMER ADJUVANT | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20170008977-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9446144-B2 | Glycopeptide and uses thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9211345-B2 | Glycopeptide and uses thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150299290-A1 | IMMUNOGENIC VACCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-20150087806-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20140212473-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130236486-A1 | IMMUNOGENIC VACCINE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2013036543-A2 | MOLECULAR IMAGING OF CANCER CELLS IN VIVO | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120039984-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-7820797-B2 | the glycolipopeptide combines features from a B-epitope glycan or glycopeptide and a T-epitope peptide derived from glycoproteins of mammalian origin; for use as a therapeutic or prophylactic vaccine | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090041836-A1 | the glycolipopeptide combines features from a B-epitope glycan or glycopeptide and a T-epitope peptide derived from glycoproteins of mammalian origin; for use as a therapeutic or prophylactic vaccine | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041836-A1 | the glycolipopeptide combines features from a B-epitope glycan or glycopeptide and a T-epitope peptide derived from glycoproteins of mammalian origin; for use as a therapeutic or prophylactic vaccine | CD4, STT3A, UGCG | TLR2 466/4885TNF 884/4885 |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-20140212473-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | TLR2 551/4885TNF 888/4885 |
| US-20250090658-A1 | POLYMER ADJUVANT | TLR3, TLR9, TLR1 | TLR2 9/4885TNF 85/4885 |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-20170008977-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | TLR2 551/4885TNF 888/4885 |
| US-20150299290-A1 | IMMUNOGENIC VACCINE | MUC1, LGALS3BP, LGALS2 | TLR2 176/4885TNF 1276/4885 |
| US-20150087806-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | TLR2 551/4885TNF 888/4885 |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-20120039984-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | TLR2 551/4885TNF 888/4885 |
| US-20130236486-A1 | IMMUNOGENIC VACCINE | MUC1, LGALS3BP, LGALS2 | TLR2 176/4885TNF 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.